Texas Attorney General Ken Paxton has announced an investigation into two pharmaceutical companies that allegedly promote the use of hormone blocking drugs for children.
The drugs are not approved by the Food and Drug Administration for this purpose.
Paxton’s office is looking into whether or not Endo Pharmaceuticals, Inc. and AbbVie Inc. violated the Texas Deceptive Trade Practices Act by promoting using the medications Supprelin LA and Lupron Depot for kids whose parents allege that they are transgender.
According to a press release from the Attorney General, “Supprelin LA and Lupron Depot are approved to treat children with Central Precocious Puberty (CPP), when the puberty process begins prematurely. And Vantas, along with other forms of Lupron, has been prescribed for palliative treatment of prostate cancer. These drugs are now being used to treat gender dysphoria even though they are not approved for such use by the Food and Drug Administration (FDA). Gender dysphoria is a diagnosed mental disorder in which a person experiences significant distress related to a strong desire to be of another biological sex.”
“The manufacture, sale, prescription, and use of puberty blockers on young teens and minors is dangerous and reckless,” Attorney General Paxton said in the statement. “These drugs were approved for very different purposes and can have detrimental and even irreversible side effects. I will not allow pharmaceutical companies to take advantage of Texas children.”
